Global Infectious Disease Testing

Infectious Disease Testing Comprehensive Study by Type (Assays, Kits, & Reagents, Instruments, Services and Software), Disease Type (Hepatitis, HIV, CT/NG, HAIs, HPV, TB, Influenza, Others), Technology (Immunodiagnostics, Clinical Microbiology, PCR, INAAT, DNA Sequencing & NGS, DNA Microarrays, Others), End User (Hospitals/Clinical Laboratories, Reference Laboratories, Physician Offices, Academic/Research Institutes, Others) Players and Region - Global Market Outlook to 2030

Infectious Disease Testing Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Infectious Disease Testing
Infectious disease is caused by bacteria, viruses, and others and has a huge impact on the healthcare systems of the countries. Infectious disease testing is the process of identification of causative organisms for the primary diagnosis of diseases. Infectious diseases testing samples include blood, urine, and other bodily fluids. Growing demand for rapid diagnostic techniques over the current techniques owing to the long turnaround time and supportive government funding along with the growing awareness for early detection using specific diagnostic tests is the major factor driving the growth of the global infectious disease testing market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR8.0%


Market players are focusing on providing wheatgrass powder with higher quality along with complying all regulatory standards to fascinate more end users. They are also focusing on the introduction of numerous advanced & attractive features to further offer qualified wheatgrass powder. The market is fragmented owing to the presence of several international and local providers. The high focus on the offering cost effective product offerings. Besides, the numerous industry profitability has led the entry of new players, in turn, increasing the level of rivalry in the already competitive market. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Infectious Disease Testing market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Abbott Laboratories (United States), Becton, Dickinson, and Company (United States), Biomérieux SA (France), Bio-Rad Laboratories (United States), Danaher Corporation (United States), Diasorin (Italy), Luminex (United States), Meridian Bioscience (United States), Quidel (United States) and Siemens AG (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Roche Diagnostics (Switzerland) and Thermo Fisher Scientific (United States).

Segmentation Overview
AMA Research has segmented the market of Global Infectious Disease Testing market by Type (Assays, Kits, & Reagents, Instruments and Services and Software) and Region.



On the basis of geography, the market of Infectious Disease Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease Type, the sub-segment i.e. Hepatitis will boost the Infectious Disease Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. Immunodiagnostics will boost the Infectious Disease Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals/Clinical Laboratories will boost the Infectious Disease Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Demand for Rapid Diagnostic Techniques

Market Growth Drivers:
Increasing Prevalence of Infectious Diseases across the Globe, Growing Inclination for Centralized Laboratories to Decentralized Point-of-Care Testing and Rising in Funding for Research on Infectious Disease Diagnostics

Challenges:
Rising Healthcare Costs Limiting the use of Novel Diagnostic Techniques

Restraints:
Inadequate Reimbursements Hindering the Growth of the Market

Opportunities:
Advances in Genomics and Proteomics and Growing Awareness about Personalized Medicine

Market Leaders and their expansionary development strategies
In March 2023, The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), the United States Agency for International Development (USAID) and the Stop TB. This collaboration will expand equitable access to quality rapid testing to underserved populations across all countries supported by the Global Fund, USAID and the Stop TB Partnership.
In December 2022, Roche announced the launch of the first infectious disease tests on the cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. These include cobas HIV-1, cobas HBV, cobas HCV, cobas HIV-1/HIV-2 Qualitative, and the cobas omni Utility Channel kit. These launches expand the Roche Molecular portfolio offering by providing standardised performance and efficiencies across low, medium and high volume molecular laboratory testing needs.


Key Target Audience
Infectious Disease Testing Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Assays, Kits, & Reagents
  • Instruments
  • Services and Software
By Disease Type
  • Hepatitis
  • HIV
  • CT/NG
  • HAIs
  • HPV
  • TB
  • Influenza
  • Others

By Technology
  • Immunodiagnostics
  • Clinical Microbiology
  • PCR
  • INAAT
  • DNA Sequencing & NGS
  • DNA Microarrays
  • Others

By End User
  • Hospitals/Clinical Laboratories
  • Reference Laboratories
  • Physician Offices
  • Academic/Research Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Infectious Diseases across the Globe
      • 3.2.2. Growing Inclination for Centralized Laboratories to Decentralized Point-of-Care Testing
      • 3.2.3. Rising in Funding for Research on Infectious Disease Diagnostics
    • 3.3. Market Challenges
      • 3.3.1. Rising Healthcare Costs Limiting the use of Novel Diagnostic Techniques
    • 3.4. Market Trends
      • 3.4.1. Growing Demand for Rapid Diagnostic Techniques
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Infectious Disease Testing, by Type, Disease Type, Technology, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Infectious Disease Testing (Value)
      • 5.2.1. Global Infectious Disease Testing by: Type (Value)
        • 5.2.1.1. Assays, Kits, & Reagents
        • 5.2.1.2. Instruments
        • 5.2.1.3. Services and Software
      • 5.2.2. Global Infectious Disease Testing by: Disease Type (Value)
        • 5.2.2.1. Hepatitis
        • 5.2.2.2. HIV
        • 5.2.2.3. CT/NG
        • 5.2.2.4. HAIs
        • 5.2.2.5. HPV
        • 5.2.2.6. TB
        • 5.2.2.7. Influenza
        • 5.2.2.8. Others
      • 5.2.3. Global Infectious Disease Testing by: Technology (Value)
        • 5.2.3.1. Immunodiagnostics
        • 5.2.3.2. Clinical Microbiology
        • 5.2.3.3. PCR
        • 5.2.3.4. INAAT
        • 5.2.3.5. DNA Sequencing & NGS
        • 5.2.3.6. DNA Microarrays
        • 5.2.3.7. Others
      • 5.2.4. Global Infectious Disease Testing by: End User (Value)
        • 5.2.4.1. Hospitals/Clinical Laboratories
        • 5.2.4.2. Reference Laboratories
        • 5.2.4.3. Physician Offices
        • 5.2.4.4. Academic/Research Institutes
        • 5.2.4.5. Others
      • 5.2.5. Global Infectious Disease Testing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Infectious Disease Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Becton, Dickinson, and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biomérieux SA (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bio-Rad Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Danaher Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Diasorin (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Luminex (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Meridian Bioscience (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Quidel (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Siemens AG (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Infectious Disease Testing Sale, by Type, Disease Type, Technology, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Infectious Disease Testing (Value)
      • 7.2.1. Global Infectious Disease Testing by: Type (Value)
        • 7.2.1.1. Assays, Kits, & Reagents
        • 7.2.1.2. Instruments
        • 7.2.1.3. Services and Software
      • 7.2.2. Global Infectious Disease Testing by: Disease Type (Value)
        • 7.2.2.1. Hepatitis
        • 7.2.2.2. HIV
        • 7.2.2.3. CT/NG
        • 7.2.2.4. HAIs
        • 7.2.2.5. HPV
        • 7.2.2.6. TB
        • 7.2.2.7. Influenza
        • 7.2.2.8. Others
      • 7.2.3. Global Infectious Disease Testing by: Technology (Value)
        • 7.2.3.1. Immunodiagnostics
        • 7.2.3.2. Clinical Microbiology
        • 7.2.3.3. PCR
        • 7.2.3.4. INAAT
        • 7.2.3.5. DNA Sequencing & NGS
        • 7.2.3.6. DNA Microarrays
        • 7.2.3.7. Others
      • 7.2.4. Global Infectious Disease Testing by: End User (Value)
        • 7.2.4.1. Hospitals/Clinical Laboratories
        • 7.2.4.2. Reference Laboratories
        • 7.2.4.3. Physician Offices
        • 7.2.4.4. Academic/Research Institutes
        • 7.2.4.5. Others
      • 7.2.5. Global Infectious Disease Testing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Infectious Disease Testing: by Type(USD Million)
  • Table 2. Infectious Disease Testing Assays, Kits, & Reagents , by Region USD Million (2018-2023)
  • Table 3. Infectious Disease Testing Instruments , by Region USD Million (2018-2023)
  • Table 4. Infectious Disease Testing Services and Software , by Region USD Million (2018-2023)
  • Table 5. Infectious Disease Testing: by Disease Type(USD Million)
  • Table 6. Infectious Disease Testing Hepatitis , by Region USD Million (2018-2023)
  • Table 7. Infectious Disease Testing HIV , by Region USD Million (2018-2023)
  • Table 8. Infectious Disease Testing CT/NG , by Region USD Million (2018-2023)
  • Table 9. Infectious Disease Testing HAIs , by Region USD Million (2018-2023)
  • Table 10. Infectious Disease Testing HPV , by Region USD Million (2018-2023)
  • Table 11. Infectious Disease Testing TB , by Region USD Million (2018-2023)
  • Table 12. Infectious Disease Testing Influenza , by Region USD Million (2018-2023)
  • Table 13. Infectious Disease Testing Others , by Region USD Million (2018-2023)
  • Table 14. Infectious Disease Testing: by Technology(USD Million)
  • Table 15. Infectious Disease Testing Immunodiagnostics , by Region USD Million (2018-2023)
  • Table 16. Infectious Disease Testing Clinical Microbiology , by Region USD Million (2018-2023)
  • Table 17. Infectious Disease Testing PCR , by Region USD Million (2018-2023)
  • Table 18. Infectious Disease Testing INAAT , by Region USD Million (2018-2023)
  • Table 19. Infectious Disease Testing DNA Sequencing & NGS , by Region USD Million (2018-2023)
  • Table 20. Infectious Disease Testing DNA Microarrays , by Region USD Million (2018-2023)
  • Table 21. Infectious Disease Testing Others , by Region USD Million (2018-2023)
  • Table 22. Infectious Disease Testing: by End User(USD Million)
  • Table 23. Infectious Disease Testing Hospitals/Clinical Laboratories , by Region USD Million (2018-2023)
  • Table 24. Infectious Disease Testing Reference Laboratories , by Region USD Million (2018-2023)
  • Table 25. Infectious Disease Testing Physician Offices , by Region USD Million (2018-2023)
  • Table 26. Infectious Disease Testing Academic/Research Institutes , by Region USD Million (2018-2023)
  • Table 27. Infectious Disease Testing Others , by Region USD Million (2018-2023)
  • Table 28. South America Infectious Disease Testing, by Country USD Million (2018-2023)
  • Table 29. South America Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 30. South America Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 31. South America Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 32. South America Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 33. Brazil Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 34. Brazil Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 35. Brazil Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 36. Brazil Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 37. Argentina Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 38. Argentina Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 39. Argentina Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 40. Argentina Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 41. Rest of South America Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 42. Rest of South America Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 43. Rest of South America Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 44. Rest of South America Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 45. Asia Pacific Infectious Disease Testing, by Country USD Million (2018-2023)
  • Table 46. Asia Pacific Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 47. Asia Pacific Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 48. Asia Pacific Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 49. Asia Pacific Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 50. China Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 51. China Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 52. China Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 53. China Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 54. Japan Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 55. Japan Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 56. Japan Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 57. Japan Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 58. India Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 59. India Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 60. India Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 61. India Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 62. South Korea Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 63. South Korea Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 64. South Korea Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 65. South Korea Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 66. Taiwan Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 67. Taiwan Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 68. Taiwan Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 69. Taiwan Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 70. Australia Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 71. Australia Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 72. Australia Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 73. Australia Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 74. Rest of Asia-Pacific Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 75. Rest of Asia-Pacific Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 76. Rest of Asia-Pacific Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 77. Rest of Asia-Pacific Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 78. Europe Infectious Disease Testing, by Country USD Million (2018-2023)
  • Table 79. Europe Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 80. Europe Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 81. Europe Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 82. Europe Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 83. Germany Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 84. Germany Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 85. Germany Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 86. Germany Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 87. France Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 88. France Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 89. France Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 90. France Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 91. Italy Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 92. Italy Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 93. Italy Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 94. Italy Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 95. United Kingdom Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 96. United Kingdom Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 97. United Kingdom Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 98. United Kingdom Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 99. Netherlands Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 100. Netherlands Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 101. Netherlands Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 102. Netherlands Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 103. Rest of Europe Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 104. Rest of Europe Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 105. Rest of Europe Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 106. Rest of Europe Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 107. MEA Infectious Disease Testing, by Country USD Million (2018-2023)
  • Table 108. MEA Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 109. MEA Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 110. MEA Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 111. MEA Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 112. Middle East Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 113. Middle East Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 114. Middle East Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 115. Middle East Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 116. Africa Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 117. Africa Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 118. Africa Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 119. Africa Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 120. North America Infectious Disease Testing, by Country USD Million (2018-2023)
  • Table 121. North America Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 122. North America Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 123. North America Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 124. North America Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 125. United States Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 126. United States Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 127. United States Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 128. United States Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 129. Canada Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 130. Canada Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 131. Canada Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 132. Canada Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 133. Mexico Infectious Disease Testing, by Type USD Million (2018-2023)
  • Table 134. Mexico Infectious Disease Testing, by Disease Type USD Million (2018-2023)
  • Table 135. Mexico Infectious Disease Testing, by Technology USD Million (2018-2023)
  • Table 136. Mexico Infectious Disease Testing, by End User USD Million (2018-2023)
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Infectious Disease Testing: by Type(USD Million)
  • Table 148. Infectious Disease Testing Assays, Kits, & Reagents , by Region USD Million (2025-2030)
  • Table 149. Infectious Disease Testing Instruments , by Region USD Million (2025-2030)
  • Table 150. Infectious Disease Testing Services and Software , by Region USD Million (2025-2030)
  • Table 151. Infectious Disease Testing: by Disease Type(USD Million)
  • Table 152. Infectious Disease Testing Hepatitis , by Region USD Million (2025-2030)
  • Table 153. Infectious Disease Testing HIV , by Region USD Million (2025-2030)
  • Table 154. Infectious Disease Testing CT/NG , by Region USD Million (2025-2030)
  • Table 155. Infectious Disease Testing HAIs , by Region USD Million (2025-2030)
  • Table 156. Infectious Disease Testing HPV , by Region USD Million (2025-2030)
  • Table 157. Infectious Disease Testing TB , by Region USD Million (2025-2030)
  • Table 158. Infectious Disease Testing Influenza , by Region USD Million (2025-2030)
  • Table 159. Infectious Disease Testing Others , by Region USD Million (2025-2030)
  • Table 160. Infectious Disease Testing: by Technology(USD Million)
  • Table 161. Infectious Disease Testing Immunodiagnostics , by Region USD Million (2025-2030)
  • Table 162. Infectious Disease Testing Clinical Microbiology , by Region USD Million (2025-2030)
  • Table 163. Infectious Disease Testing PCR , by Region USD Million (2025-2030)
  • Table 164. Infectious Disease Testing INAAT , by Region USD Million (2025-2030)
  • Table 165. Infectious Disease Testing DNA Sequencing & NGS , by Region USD Million (2025-2030)
  • Table 166. Infectious Disease Testing DNA Microarrays , by Region USD Million (2025-2030)
  • Table 167. Infectious Disease Testing Others , by Region USD Million (2025-2030)
  • Table 168. Infectious Disease Testing: by End User(USD Million)
  • Table 169. Infectious Disease Testing Hospitals/Clinical Laboratories , by Region USD Million (2025-2030)
  • Table 170. Infectious Disease Testing Reference Laboratories , by Region USD Million (2025-2030)
  • Table 171. Infectious Disease Testing Physician Offices , by Region USD Million (2025-2030)
  • Table 172. Infectious Disease Testing Academic/Research Institutes , by Region USD Million (2025-2030)
  • Table 173. Infectious Disease Testing Others , by Region USD Million (2025-2030)
  • Table 174. South America Infectious Disease Testing, by Country USD Million (2025-2030)
  • Table 175. South America Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 176. South America Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 177. South America Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 178. South America Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 179. Brazil Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 180. Brazil Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 181. Brazil Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 182. Brazil Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 183. Argentina Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 184. Argentina Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 185. Argentina Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 186. Argentina Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 187. Rest of South America Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 188. Rest of South America Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 189. Rest of South America Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 190. Rest of South America Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 191. Asia Pacific Infectious Disease Testing, by Country USD Million (2025-2030)
  • Table 192. Asia Pacific Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 193. Asia Pacific Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 194. Asia Pacific Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 195. Asia Pacific Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 196. China Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 197. China Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 198. China Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 199. China Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 200. Japan Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 201. Japan Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 202. Japan Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 203. Japan Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 204. India Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 205. India Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 206. India Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 207. India Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 208. South Korea Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 209. South Korea Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 210. South Korea Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 211. South Korea Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 212. Taiwan Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 213. Taiwan Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 214. Taiwan Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 215. Taiwan Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 216. Australia Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 217. Australia Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 218. Australia Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 219. Australia Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 220. Rest of Asia-Pacific Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 221. Rest of Asia-Pacific Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 222. Rest of Asia-Pacific Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 223. Rest of Asia-Pacific Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 224. Europe Infectious Disease Testing, by Country USD Million (2025-2030)
  • Table 225. Europe Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 226. Europe Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 227. Europe Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 228. Europe Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 229. Germany Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 230. Germany Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 231. Germany Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 232. Germany Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 233. France Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 234. France Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 235. France Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 236. France Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 237. Italy Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 238. Italy Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 239. Italy Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 240. Italy Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 241. United Kingdom Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 242. United Kingdom Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 243. United Kingdom Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 244. United Kingdom Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 245. Netherlands Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 246. Netherlands Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 247. Netherlands Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 248. Netherlands Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 249. Rest of Europe Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 250. Rest of Europe Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 251. Rest of Europe Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 252. Rest of Europe Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 253. MEA Infectious Disease Testing, by Country USD Million (2025-2030)
  • Table 254. MEA Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 255. MEA Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 256. MEA Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 257. MEA Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 258. Middle East Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 259. Middle East Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 260. Middle East Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 261. Middle East Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 262. Africa Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 263. Africa Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 264. Africa Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 265. Africa Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 266. North America Infectious Disease Testing, by Country USD Million (2025-2030)
  • Table 267. North America Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 268. North America Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 269. North America Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 270. North America Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 271. United States Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 272. United States Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 273. United States Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 274. United States Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 275. Canada Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 276. Canada Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 277. Canada Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 278. Canada Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 279. Mexico Infectious Disease Testing, by Type USD Million (2025-2030)
  • Table 280. Mexico Infectious Disease Testing, by Disease Type USD Million (2025-2030)
  • Table 281. Mexico Infectious Disease Testing, by Technology USD Million (2025-2030)
  • Table 282. Mexico Infectious Disease Testing, by End User USD Million (2025-2030)
  • Table 283. Research Programs/Design for This Report
  • Table 284. Key Data Information from Secondary Sources
  • Table 285. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Infectious Disease Testing: by Type USD Million (2018-2023)
  • Figure 5. Global Infectious Disease Testing: by Disease Type USD Million (2018-2023)
  • Figure 6. Global Infectious Disease Testing: by Technology USD Million (2018-2023)
  • Figure 7. Global Infectious Disease Testing: by End User USD Million (2018-2023)
  • Figure 8. South America Infectious Disease Testing Share (%), by Country
  • Figure 9. Asia Pacific Infectious Disease Testing Share (%), by Country
  • Figure 10. Europe Infectious Disease Testing Share (%), by Country
  • Figure 11. MEA Infectious Disease Testing Share (%), by Country
  • Figure 12. North America Infectious Disease Testing Share (%), by Country
  • Figure 13. Global Infectious Disease Testing share by Players 2023 (%)
  • Figure 14. Global Infectious Disease Testing share by Players (Top 3) 2023(%)
  • Figure 15. Global Infectious Disease Testing share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 19. Becton, Dickinson, and Company (United States) Revenue, Net Income and Gross profit
  • Figure 20. Becton, Dickinson, and Company (United States) Revenue: by Geography 2023
  • Figure 21. Biomérieux SA (France) Revenue, Net Income and Gross profit
  • Figure 22. Biomérieux SA (France) Revenue: by Geography 2023
  • Figure 23. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 24. Bio-Rad Laboratories (United States) Revenue: by Geography 2023
  • Figure 25. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 26. Danaher Corporation (United States) Revenue: by Geography 2023
  • Figure 27. Diasorin (Italy) Revenue, Net Income and Gross profit
  • Figure 28. Diasorin (Italy) Revenue: by Geography 2023
  • Figure 29. Luminex (United States) Revenue, Net Income and Gross profit
  • Figure 30. Luminex (United States) Revenue: by Geography 2023
  • Figure 31. Meridian Bioscience (United States) Revenue, Net Income and Gross profit
  • Figure 32. Meridian Bioscience (United States) Revenue: by Geography 2023
  • Figure 33. Quidel (United States) Revenue, Net Income and Gross profit
  • Figure 34. Quidel (United States) Revenue: by Geography 2023
  • Figure 35. Siemens AG (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Siemens AG (Germany) Revenue: by Geography 2023
  • Figure 37. Global Infectious Disease Testing: by Type USD Million (2025-2030)
  • Figure 38. Global Infectious Disease Testing: by Disease Type USD Million (2025-2030)
  • Figure 39. Global Infectious Disease Testing: by Technology USD Million (2025-2030)
  • Figure 40. Global Infectious Disease Testing: by End User USD Million (2025-2030)
  • Figure 41. South America Infectious Disease Testing Share (%), by Country
  • Figure 42. Asia Pacific Infectious Disease Testing Share (%), by Country
  • Figure 43. Europe Infectious Disease Testing Share (%), by Country
  • Figure 44. MEA Infectious Disease Testing Share (%), by Country
  • Figure 45. North America Infectious Disease Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Becton, Dickinson, and Company (United States)
  • Biomérieux SA (France)
  • Bio-Rad Laboratories (United States)
  • Danaher Corporation (United States)
  • Diasorin (Italy)
  • Luminex (United States)
  • Meridian Bioscience (United States)
  • Quidel (United States)
  • Siemens AG (Germany)
Additional players considered in the study are as follows:
Roche Diagnostics (Switzerland) , Thermo Fisher Scientific (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 218 Pages 63 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Infectious Disease Testing Quantitative research analysis
Global Infectious Disease Testing Qualitative Industry Analysis
Global Infectious Disease Testing Quantitative research analysis
Global Infectious Disease Testing Qualitative Industry Analysis
Global Infectious Disease Testing Quantitative research analysis
Global Infectious Disease Testing Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Abbott Laboratories (United States), Becton, Dickinson, and Company (United States), Biomérieux SA (France), Bio-Rad Laboratories (United States), Danaher Corporation (United States), Diasorin (Italy), Luminex (United States), Meridian Bioscience (United States), Quidel (United States) and Siemens AG (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Demand for Rapid Diagnostic Techniques" is seen as one of major influencing trends for Infectious Disease Testing Market during projected period 2023-2030.
The Infectious Disease Testing market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Infectious Disease Testing Report?

Have a Query? Click Here

Other Related Reports

Infertility Treatment Comprehensive Study by Application (Fertility Centers, Hospitals and Surgical Clinics, Research Institutes, Cryobanks), Equipment (Microscopes, Imaging Systems, Incubators, Sper...
$ 3750
Pediatric Interventional Cardiology Comprehensive Study by Type (Congenital Heart Defect Closure Devices (Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), and Patent Foramen Ovale (PFO) C...
$ 3750
Animal Stem Cell Therapy Comprehensive Study by Type (Dogs, Cats, Horses, Others), Application (Osteoarthritis, Injuries to bones, Joints, Tendons, Ligament, Spinal cord, Others), Sources (Embryonic ...
$ 3650
Neuropathy Pain Treatment Comprehensive Study by Type (Peripheral Neuropathy, Entrapment Neuropathy, Post Traumatic Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Phantom Limb Pain,...
$ 3750
Vitamin Deficiency Treatment Comprehensive Study by Type (Multivitamin Deficiency Treatment, Single Vitamin Deficiency Treatment), End Users (Adults, Kids), Route of Administration (Oral, Parenteral)...
$ 3650
Insulin Lispro Comprehensive Study by Type (Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin), Application (Type 1 Diabetes, Type 2 Diabetes), Distribution...
$ 3450
Infertility Treatment Comprehensive Study by Application (Fertility Centers, Hospitals and Surgical Clinics, Research Institutes, Cryobanks), Equipment (Microscopes, Imaging Systems, Incubators, Sper...
$ 3750
Pediatric Interventional Cardiology Comprehensive Study by Type (Congenital Heart Defect Closure Devices (Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), and Patent Foramen Ovale (PFO) C...
$ 3750
Animal Stem Cell Therapy Comprehensive Study by Type (Dogs, Cats, Horses, Others), Application (Osteoarthritis, Injuries to bones, Joints, Tendons, Ligament, Spinal cord, Others), Sources (Embryonic ...
$ 3650
Neuropathy Pain Treatment Comprehensive Study by Type (Peripheral Neuropathy, Entrapment Neuropathy, Post Traumatic Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Phantom Limb Pain,...
$ 3750
Vitamin Deficiency Treatment Comprehensive Study by Type (Multivitamin Deficiency Treatment, Single Vitamin Deficiency Treatment), End Users (Adults, Kids), Route of Administration (Oral, Parenteral)...
$ 3650
Insulin Lispro Comprehensive Study by Type (Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin), Application (Type 1 Diabetes, Type 2 Diabetes), Distribution...
$ 3450
Infertility Treatment Comprehensive Study by Application (Fertility Centers, Hospitals and Surgical Clinics, Research Institutes, Cryobanks), Equipment (Microscopes, Imaging Systems, Incubators, Sper...
$ 3750
Pediatric Interventional Cardiology Comprehensive Study by Type (Congenital Heart Defect Closure Devices (Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), and Patent Foramen Ovale (PFO) C...
$ 3750
Animal Stem Cell Therapy Comprehensive Study by Type (Dogs, Cats, Horses, Others), Application (Osteoarthritis, Injuries to bones, Joints, Tendons, Ligament, Spinal cord, Others), Sources (Embryonic ...
$ 3650
Neuropathy Pain Treatment Comprehensive Study by Type (Peripheral Neuropathy, Entrapment Neuropathy, Post Traumatic Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Phantom Limb Pain,...
$ 3750